Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Revenue projections:

Revenue projections for SPARC
Revenue projections for SPARC

Sun Pharma Advanced Research Company Limited's revenue projections show growth above last year's levels, which could indicate a solid investment opportunity. Investors may find the company's rising financial performance attractive if confirmed by other fundamental indicators, suggesting it has the potential for future gains.

Financial Ratios:

currentRatio 0.02900
forwardPE 0.00000
debtToEquity 0.00000
earningsGrowth 0.00000
revenueGrowth -0.38900
grossMargins 0.52027
operatingMargins -8.68702
trailingEps -8.23000
forwardEps 55.40000

With a current ratio of 0.029, SPARC may not have enough cash reserves and current assets to cover its short-term debts. This suggests potential liquidity concerns, as the company may struggle to meet its immediate financial obligations.
SPARC's low growth in both earnings and revenue indicates the company's profits may decrease. This trend could signal a downturn in financial performance, suggesting that SPARC might struggle to maintain its current profit levels.

Price projections:

Price projections for SPARC
Price projections for SPARC



Recommendation changes over time:

Recommendations trend for SPARC
Recommendations trend for SPARC


SPARC has garnered a buy bias from analysts recently, suggesting the stock is a good investment opportunity. This may lead to increased investor interest, as SPARC is seen as a reliable place to park money for those looking to benefit from potential market gains and company growth.